{
    "clinical_study": {
        "@rank": "80860", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive a stem cell transplantation along with a non-marrow ablative conditioning regimen containing total bdoy irradiation combined with post-transplant immunosuppression with cyclosporine and mycophenolate mofetil"
        }, 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the safety of total body irradiation and post-transplant cyclosporine and\n      mycophenolate mofetil in high-risk patients with human immunodeficiency virus-1.\n\n      II. Determine whether this regimen results in stable mixed donor lymphocyte chimerism (5-95%\n      donor CD3) in this patient population.\n\n      III. Determine the kinetics of immune reconstruction following this treatment regimen in\n      this patient population.\n\n      IV. Determine the effect of this treatment regimen on viral load in this patient population."
        }, 
        "brief_title": "Study of Total Body Irradiation in Combination With Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation Followed By Cyclosporine and Mycophenolate Mofetil in High Risk-Patients With Human Immunodeficiency Virus-1", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive oral or IV cyclosporine 2-3 times daily on Days -1 to 50. Patients undergo\n      total body irradiation followed by allogeneic peripheral blood stem cell or bone marrow\n      transplantation on Day 0 (assuming donor is available). Beginning within 6 hours of\n      transplantation, patients receive oral mycophenolate mofetil every 12 hours until Day 27.\n\n      Patients with an unstable level of chimerism may receive 1-2 donor lymphocyte infusions.\n\n      Patients are followed at Days 14, 28, 56, 80, 180, and 360."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of human immunodeficiency virus-1 not responsive to highly active\n             antiretroviral therapy (HAART); treated with HAART for at least the past 6 months;\n             viral load less than 50 copies/mL plasma; CD4 count less than 100/mm3\n\n          -  Lymphoma or other HIV-associated malignancy allowed with the following criteria:\n             malignancy is in complete remission or very good partial remission, defined as a\n             significant reduction of disease with therapy and no evidence of continued tumor\n             growth; viral load has decreased by at least 1.5 logs OR to less than 5,000 copies/mL\n             plasma while on HAART; CD4 count is allowed to be greater than 100/mm3\n\n          -  HLA genotypically identical donor available (under 75 years of age)\n\n        --Prior/Concurrent Therapy--\n\n          -  No concurrent growth factors during mycophenolate mofetil administration; concurrent\n             continuation of anti-retroviral therapy required\n\n        --Patient Characteristics--\n\n          -  Life expectancy: At least 30 days\n\n          -  Other: No positive serology for Toxoplasma gondii; no other disease or organ\n             dysfunction that would preclude survival; not pregnant or nursing; fertile patients\n             must use effective contraception during and for 1 year after study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 2, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00010348", 
            "org_study_id": "199/15576", 
            "secondary_id": "FHCRC-1410.00"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "Oral or IV cyclosporine 2 to 3 times daily on Days -1 to 50", 
                "intervention_name": "Cyclosporine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1", 
                "description": "Beginning within 6 hours of transplantation, oral mycophenolate mofetil every 12 hours until Day 27.", 
                "intervention_name": "Mycophenolate mofetil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1", 
                "description": "Assuming donor is available, total body irradiation followed by allogeneic peripheral blood stem cell or bone marrow transplantation on Day 0.", 
                "intervention_name": "Total body irradiation and stem cell or bone marrow transplantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Mycophenolic Acid", 
                "Mycophenolate mofetil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "human immunodeficiency virus infection", 
            "immunologic disorders and infectious disorders", 
            "rare disease", 
            "viral infection"
        ], 
        "lastchanged_date": "May 13, 2009", 
        "location": {
            "contact": {
                "last_name": "Ann Woolfrey", 
                "phone": "206-667-4453"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center", 
            "last_name": "Ann Woolfrey", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mortality due to infection, donor chimerism", 
            "safety_issue": "Yes", 
            "time_frame": "Days 14, 28, 56, 80, 180, and 360"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00010348"
        }, 
        "responsible_party": {
            "name_title": "Ann Woolfrey / Associate in Clinical Research", 
            "organization": "Fred Hutchinson Cancer Research Center"
        }, 
        "secondary_outcome": {
            "measure": "CD4, viral load", 
            "safety_issue": "Yes", 
            "time_frame": "Days 14, 28, 56, 80, 180, and 360"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2000", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2009"
    }, 
    "geocoordinates": {
        "Fred Hutchinson Cancer Research Center": "47.606 -122.332"
    }
}